Abstract:Alzheimer's disease (AD) is a severe neurodegenerative disorder of the brain that manifests as dementia, disorientation, difficulty in speech, and progressive cognitive and behavioral impairment. The emerging therapeutic approach to AD management is the inhibition of beta-site APP cleaving enzyme-1 (BACE1), known to be one of the two aspartyl proteases that cleave beta-amyloid precursor protein (APP). Studies confirmed the association of high BACE1 activity with the proficiency in the formation of beta-amyloid-containing neurotic plaques, the characteristics of AD. Only a few FDA-approved BACE1 inhibitors are available in the market, but their adverse off-target effects limit their usage. In this paper, we have used both ligand-based and target-based approaches for drug design. The QSAR study entails creating a multivariate GA-MLR (Genetic Algorithm-Multilinear Regression) model using 552 molecules with acceptable statistical performance (R-2 = 0.82, Q(loo)(2) = 0.81). According to the QSAR study, the activity has a strong link with various atoms such as aromatic carbons and ring Sulfur, acceptor atoms, sp2-hybridized oxygen, etc. Following that, a database of 26,467 food compounds was primarily used for QSAR-based virtual screening accompanied by the application of the Lipinski rule of five; the elimination of duplicates, salts, and metal derivatives resulted in a truncated dataset of 8,453 molecules. The molecular descriptor was calculated and a well-validated 6-parametric version of the QSAR model was used to predict the bioactivity of the 8,453 food compounds. Following this, the food compounds whose predicted activity (pKi) was observed above 7.0 M were further docked into the BACE1 receptor which gave rise to the Identification of 4-(3,4-Dihydroxyphenyl)-2-hydroxy-1H-phenalen-1-one (PubChem I.D: 4468; Food I.D: FDB017657) as a hit molecule (Binding Affinity = -8.9 kcal/mol, pKi = 7.97 nM, Ki = 10.715 M). Furthermore, molecular dynamics simulation for 150 ns and molecular mechanics generalized born and surface area (MMGBSA) study aided in identifying structural motifs involved in interactions with the BACE1 enzyme. Molecular docking and QSAR yielded complementary and congruent results. The validated analyses can be used to improve a drug/lead candidate's inhibitory efficacy against the BACE1. Thus, our approach is expected to widen the field of study of repurposing nutraceuticals into neuroprotective as well as anti-cancer and anti-viral therapeutic interventions.

Bacopa monnieri phytochemicals as promising BACE1 inhibitors for Alzheimers Disease Therapy

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

A Computational Study of Natural Compounds from Bacopa Monnieri in the Treatment of Alzheimer's Disease.

Molecular docking analysis of marine phytochemicals with BACE-1

Virtual screening, ADMET prediction, molecular docking, and dynamic simulation studies of natural products as BACE1 inhibitors for the management of Alzheimer's disease

BACE1 Inhibition Utilizing Organic Compounds Holds Promise as a Potential Treatment for Alzheimer's and Parkinson's Diseases

Unraveling potential neuroprotective mechanisms of herbal medicine for Alzheimer's diseases through comprehensive molecular docking analyses

Repurposing food molecules as a potential BACE1 inhibitor for Alzheimer's disease

Comprehensive Investigation of Natural Ligands as Inhibitors of β Secretase to Identify Alzheimer’s Disease Therapeutics

Machine Learning-Enhanced Drug Discovery for BACE1: A Novel Approach to Alzheimer's Therapeutics

A Close Look at BACE1 Inhibitors for Alzheimer’s Disease Treatment

Amelioration of Amyloid-β Induced Alzheimer's Disease by Bacopa monnieri through Modulation of Mitochondrial Dysfunction and GSK-3β/Wnt/β-Catenin Signaling

Computational identification of promising therapeutics via BACE1 Targeting: Implications for Alzheimer's disease

Structure‐based Virtual Screening and Biological Characterization of Novel BACE‐1 and Amyloid‐β Aggregation Inhibitors

Beta-Site APP-Cleaving Enzyme-1 Inhibitory Role of Natural Flavonoids in the Treatment of Alzheimer's Disease

Exploring the potential of Scabiosa columbaria in Alzheimer's disease treatment: An in silico approach

Revealing the Binding Mechanism of BACE1 Inhibitors Through Molecular Dynamics Simulations.

BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease

Discovery of Novel, Potent BACE Inhibitors with Central Activity for the Treatment of Alzheimer's Disease

Sulfonamido, amido heterocyclic adducts of tetrazole derivatives as BACE1 inhibitors: in silico exploration

Navigating the Maze of Alzheimer's Disease by Exploring BACE1: Discovery, Current Scenario, and Future Prospects